$MYO

Kovelman Harry sold $32K of MYO

Kovelman Harry (Chief Medical Officer) sold 32,000 shares of MYOMO, INC. (MYO) at an average of $1.01 ($1.00–$1.02) across 2 trades over 2026-05-27 to 2026-05-28.

Original reporting
SEC EDGAR · Kovelman Harry
Published May 28, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 8:42 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MYO
Neutral
medium confidence
Mentioned
$MYO
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MYONeutralLow
01

Why it matters

It reports an open-market sale by the Chief Medical Officer, totaling $32,239.35 across two trades, with holdings after the sale of 108,618 shares.

02

Market read

Traders may monitor for sentiment effects from insider selling, but the filing alone does not provide a new fundamental catalyst.

03

What to watch

The article does not state tax, option exercise context, or whether other insiders are buying; it also provides no 10b5-1 plan details, which can affect interpretation of intent.

Relevance 3/10Novelty 3/10Timing: filed 2026-05-28, covering sales on 2026-05-27 to 2026-05-28

Background

The article is a SEC Form 4 insider transaction report for MYOMO, Inc. (MYO).

Company-level read

Ticker impact

$MYONeutralMedium confidence
Context

MYOMO CMO Harry Kovelman sold 32,000 shares in open-market transactions at about $1.00 to $1.02, per a fresh Form 4 filing.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

This is a routine insider sale disclosure with no 10b5-1 plan and no accompanying company-specific news (earnings, guidance, contracts, or regulatory actions).

Market effects

No sector-level implications are provided; the disclosure is company-specific and limited to an insider transaction.

None indicated.

None indicated.

Counterpoint

Insider sales can be for diversification or liquidity needs and do not necessarily signal deteriorating business prospects, especially without any accompanying negative company event in the filing.

Key entities

  • MYOMO, Inc.

    Company whose insider sale is disclosed via Form 4.

  • Harry Kovelman

    Chief Medical Officer who sold 32,000 shares.

Related articles

$MYOHigh

MYOMO, INC. (MYO): Results of Operations and Financial Condition

MYOMO, INC. (MYO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 myo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Myomo Reports Second Quarter 2026 Financial and Operating Results Revenue of $11.7 million, increased 21% year over year Four success pillars driving higher revenue growth and operating leverage Raising full year revenue guida

$RGNTMedAI 8/10

Top Biotech Gainers: RGNT Withdraws F-1 Filing, FDA Clears CUPR's Maggot Therapy, MYO On Watch

Regentis (RGNT) shares rose 526.7% after it withdrew a planned SEC Form F-1 for a firm-commitment offering of 3.33M shares at an assumed $3.00. Cuprina (CUPR) jumped 111.8% after FDA clearance for MEDIFLY maggots for debridement of non-healing wounds. Intellia (NTLA) gained 23.2% on additional Phase 3 results for hereditary angioedema; it targets approval and a 1H 2027 launch.